Summarized by Masters of Longevity from NewLimit.
Company update on scaling LNP‑RNA manufacturing, improving product quality, and moving a reprogramming RNA therapeutic toward clinical entry.
Key Takeaways
- The company increased LNP-RNA manufacturing scale by more than 314-fold this year.
- Manufacturing quality improved about 13-fold on key measures, reaching clinical-grade levels.
- Scaled LNP-RNA formulations showed strong delivery to liver cells in preclinical models.
